Ribavirin
- PDF / 169,386 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 115 Downloads / 132 Views
1
Ribavirin Anaemia: case report In a monocentric retrospective observational study comprising of 55 patients treated with direct-acting antiviral agents from November 2014 to September 2017, a patient [age and sex not stated] was described, who developed anaemia during treatment with ribavirin for recurrent hepatitis C virus (HCV) infection. The patient, who had HCV infection, underwent liver transplantation. Subsequently, the patient developed recurrence of HCV. Therefore, the patient started receiving ribavirin [route and dosage not stated]. The patient’s concurrent medication included an unspecified immunosuppressant. The patient developed severe anaemia secondary to ribavirin therapy [duration of treatment to reaction onset not stated]. Therefore, ribavirin was discontinued [outcome not stated]. Author comment: "The most frequent adverse events were anemia associated with ribavirin." Castelletti S, et al. Therapy with direct-acting antiviral agents in transplanted patients with HCV recurrence: a retrospective analysis. Hepatitis Monthly 19: No. 7, 2019. Available from: URL: http://doi.org/10.5812/hepatmon.90624 803438002 Italy
0114-9954/19/1782-0001/$14.95 Adis © 2019 Springer Nature Switzerland AG. All rights reserved
Reactions 7 Dec 2019 No. 1782
Data Loading...
